Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Correction to: Revefenacin: First Global Approval

Correction to: Revefenacin: First Global Approval Drugs (2019) 79:689 https://doi.org/10.1007/s40265-019-01106-z CORREC TION Young‑A Heo Published online: 29 March 2019 © Springer Nature 2019 Correction to: Drugs (2019) 79:85–91 source, provide a link to the Creative Commons license and https ://doi.org/10.1007/s4026 5-018-1036-x indicate if changes were made. The article Revefenacin: First Global Approval, written by The original article has been corrected. Young-A Heo, was originally published Online First without open access. After publication in volume 79, issue 1, pages Open Access This article is distributed under the terms of the Crea- 85–91, Mylan Inc. (Canonsburg, Pennsylvania, USA) and tive Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any Theravance Biopharma US, Inc. (South San Francisco, Cali- noncommercial use, distribution, and reproduction in any medium, fornia, USA) requested that the article be Open Choice to provided you give appropriate credit to the original author(s) and the make the article an open access publication. Post-publication source, provide a link to the Creative Commons license, and indicate open access was funded by Mylan Inc. (Canonsburg, Penn- if changes were made. sylvania, USA) and Theravance Biopharma US, Inc. (South San Francisco, California, USA). The article is forthwith distributed under the terms of the Creative Commons Attri- bution-NonCommercial 4.0 International License (http:// creat iveco mmons .org/licen ses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribu- tion and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the The original article can be found online at https ://doi.org/10.1007/ s4026 5-018-1036-x. * Young-A Heo dru@adis.com Springer, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand Vol.:(0123456789) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drugs Springer Journals

Correction to: Revefenacin: First Global Approval

Heo, Young-A
Drugs , Volume 79 (6) – Mar 29, 2019
Download PDF
1 page

Loading next page...
 
/lp/springer-journals/correction-to-revefenacin-first-global-approval-B0rauzMOIF

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2019 by Springer Nature
Subject
Medicine & Public Health; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine
ISSN
0012-6667
eISSN
1179-1950
DOI
10.1007/s40265-019-01106-z
Publisher site
See Article on Publisher Site

Abstract

Drugs (2019) 79:689 https://doi.org/10.1007/s40265-019-01106-z CORREC TION Young‑A Heo Published online: 29 March 2019 © Springer Nature 2019 Correction to: Drugs (2019) 79:85–91 source, provide a link to the Creative Commons license and https ://doi.org/10.1007/s4026 5-018-1036-x indicate if changes were made. The article Revefenacin: First Global Approval, written by The original article has been corrected. Young-A Heo, was originally published Online First without open access. After publication in volume 79, issue 1, pages Open Access This article is distributed under the terms of the Crea- 85–91, Mylan Inc. (Canonsburg, Pennsylvania, USA) and tive Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any Theravance Biopharma US, Inc. (South San Francisco, Cali- noncommercial use, distribution, and reproduction in any medium, fornia, USA) requested that the article be Open Choice to provided you give appropriate credit to the original author(s) and the make the article an open access publication. Post-publication source, provide a link to the Creative Commons license, and indicate open access was funded by Mylan Inc. (Canonsburg, Penn- if changes were made. sylvania, USA) and Theravance Biopharma US, Inc. (South San Francisco, California, USA). The article is forthwith distributed under the terms of the Creative Commons Attri- bution-NonCommercial 4.0 International License (http:// creat iveco mmons .org/licen ses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribu- tion and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the The original article can be found online at https ://doi.org/10.1007/ s4026 5-018-1036-x. * Young-A Heo dru@adis.com Springer, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand Vol.:(0123456789)

Journal

Drugs – Springer Journals

Published: Mar 29, 2019

There are no references for this article.